Table 1. Published studies of recent RSV vaccine candidates tested in clinical trials in different population groups.
Vaccine | Class | Adults | Seropositive children | Seronegative children | Pregnant women | Older adults |
---|---|---|---|---|---|---|
FI-RSV (14, 17) | FIV* | |||||
F, G, M subunit (89, 90] | Subunit | |||||
F-nanoparticle (55, 81] | Nanoparticle | |||||
Chimpanzee adenovirus RSV vaccine (39) | VVV† | |||||
BBG2Na (91, 92) | Subunit | |||||
ΔM2-2 (93) | LAV‡ | |||||
rA2cp248/404/1030ΔSH (94) | LAV | |||||
cpts530/1009 (35) | LAV | |||||
RSV ts-2 (95) | LAV | |||||
MEDI-559 (96) | LAV | |||||
MEDI-534 (97–99) | LAV | |||||
RSV ts-1 A, B, and C (100, 101) | LAV | |||||
cpts248/955 (35) | LAV | |||||
cp-52B (102) | LAV | |||||
rA2cpΔNS2 (103) | LAV | |||||
cpRSV (104, 105) | LAV | |||||
RSV ts-1 (106–108) | LAV | |||||
Cpts248/404 (109,110) | LAV | |||||
rA2cp248/404ΔSH (94) | LAV | |||||
rA2cp248/404/1030ΔNS2 (103) | LAV | |||||
rA2cp530/1009ΔNS2 (103) | LAV | |||||
PFP1 (111–116) | Subunit | |||||
PFP2 (110, 117–121) | Subunit | |||||
PFP3 (122) | Subunit | |||||
MEDI-7510 (123) | Subunit | |||||
F nanoparticle (124, 125) | Nanoparticle | |||||
Pre-F (126) | Subunit | |||||
Soluble post-F (127) | Subunit | |||||
Small hydrophobic protein ectodomain (128) | Subunit | |||||
RSVcps2 (129) | LAV | |||||
LIDΔM2-2 (130) | LAV | |||||
RSV Pre-F (131) | Recombinant |
FIV, formalin-inactivated vaccine.
VVV, viral vector vaccine.
LAV, live-attenuated vaccine.